CYDY CytoDyn Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1175680 · Fiscal year ends 05/31
Financial factors as of 2026-08-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-171.6%
TTM EPS YoY-100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-351.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets614.7%
Debt / equity—
Current ratio0.38x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.39x
Accruals ratio-212.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-05-31 | FY20252025-05-31 | FY20242024-05-31 | FY20232023-05-31 | FY20222022-05-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | $0 | $266,000 |
| Cost of revenue | — | — | — | — | $53,000 |
| Gross profit | — | — | — | — | $213,000 |
| R&D expense | — | — | $7.24M | $2.63M | $27.04M |
| SG&A expense | $7.45M | $7.26M | $10.82M | $17.14M | $44.30M |
| Operating income | -$38.58M | $9.66M | -$18.06M | -$40.58M | -$145.40M |
| Interest expense | — | — | $31.78M | $39.25M | $65.42M |
| Pretax income | -$42.70M | $3.75M | -$49.84M | -$79.82M | -$210.82M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$42.70M | $3.75M | -$49.84M | -$79.82M | -$210.82M |
| EBITDA | -$38.56M | $9.68M | -$18.03M | -$40.40M | -$144.62M |
| EPS (basic) | -0.03 | 0.00 | -0.05 | -0.10 | -0.31 |
| EPS (diluted) | -0.03 | 0.00 | -0.05 | -0.10 | -0.31 |
| Weighted avg. shares (diluted) | 1.29B | 1.24B | 969.51M | 836.53M | 676.90M |
| Balance sheet | |||||
| Cash & equivalents | $11.85M | $11.90M | $9.81M | $9.05M | $4.23M |
| Inventory | — | — | $0 | $0 | — |
| Current assets | $13.88M | $17.88M | $10.81M | $10.80M | $10.52M |
| PP&E, net | — | — | — | — | $73,000 |
| Intangibles | — | — | — | — | $132,000 |
| Total assets | $13.97M | $18.05M | $11.14M | $11.29M | $29.18M |
| Current liabilities | $53.73M | $70.52M | $84.18M | $119.80M | $123.16M |
| Long-term debt | $38.34M | $45.35M | $45.02M | $45.73M | $42.22M |
| Total debt | $38.34M | $45.35M | $45.02M | $45.73M | $42.22M |
| Total liabilities | $123.69M | $114.09M | $127.89M | $120.79M | $123.58M |
| Shareholders' equity | -$109.72M | -$96.04M | -$116.76M | -$109.50M | -$94.40M |
| Net debt | $26.49M | $33.45M | $35.21M | $36.68M | $37.98M |
| Shares outstanding | 1.37B | 1.25B | 1.06B | 918.61M | 719.59M |
| Cash flow statement | |||||
| Operating cash flow | -$17.25M | -$8.77M | -$10.98M | -$25.11M | -$77.72M |
| Investing cash flow | $0 | $0 | — | — | — |
| Financing cash flow | $17.20M | $10.85M | $11.75M | $29.93M | $48.01M |
| Depreciation & amortization | $17,000 | $18,000 | $29,000 | $175,000 | $781,000 |
| Stock-based compensation | $1.63M | $1.61M | $2.42M | $4.28M | $6.24M |
Free plan shows the latest 5 periods; Pro shows all 22 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.